WEBULL
WebtradeDownload

Boston Scientific (BSX) Stock Could Be A Bargain On Strong Cash Flow Views

Simply Wall St · 20h ago

Boston Scientific has seen a sharp reset in its share price over the past year, which puts a fresh spotlight on whether today's valuation is still supported by the cash the business is expected to generate. After a period of weaker returns, the key issue for investors is how that market reaction lines up with the company’s underlying cash flow profile.

  • The share price has fallen 55.7% over the past year, which puts a lot of weight on whether the current market value still lines up with Boston Scientific's cash flow prospects.
  • The business model is built around medical devices that typically involve meaningful upfront development costs followed by recurring procedure volumes. As a result, the timing and durability of those cash inflows can materially influence any intrinsic value estimate.
  • What if you looked at Boston Scientific through its earnings instead? See what Boston Scientific's 17.1x P/E says about the price.

For investors, the debate is whether Boston Scientific's recent share price reset is now in line with what its cash flows can justify.

To compare Boston Scientific's cash flow discussion with other valuation opportunities, place it alongside 33 high quality undervalued stocks.

Does Boston Scientific Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model here focuses on the cash Boston Scientific can return to shareholders over time. Latest twelve month free cash flow sits around $3.6b, so this is already a cash generative operation rather than an early stage project where everything hinges on distant payoffs.

Analysts in the model expect those cash flows to keep growing in absolute terms, with a gradual step up rather than a dramatic surge. Against a share price of $43.34, the DCF projections put Boston Scientific's estimated intrinsic value substantially above the current share price, which suggests the recent drop has moved the market price further away from what these cash flows imply. Find out what Boston Scientific could be worth using our Discounted Cash Flow (DCF) estimate.

The Boston Scientific Narrative: What Would Justify Today's Price?

Narratives on Boston Scientific pick up where this valuation puzzle leaves off, by spelling out which paths for growth, margins and earnings would need to play out for the stock to be worth materially more or materially less than it trades for today on the market. Each narrative links its figures to a clear view on how Boston Scientific's growth profile, profitability and risk picture might evolve, giving you a reference point you can revisit as new information is released on Simply Wall St's Community page.

One of the top community narratives on Boston Scientific: 56% undervalued

"The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons..."

Discover why this Narrative puts Boston Scientific at 56% undervalued.

Boston Scientific’s valuation still leaves one crucial issue unresolved

Before leaning too hard on the cash flow story for Boston Scientific, it helps to know that separate checks have flagged specific concerns that investors may want to weigh alongside the upside narrative. Take a closer look at 1 warning sign before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.